{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:39:11Z","timestamp":1790386751967,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jad.2024.12.008","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T02:23:04Z","timestamp":1733365384000},"page":"409-419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Efficacy of orexin antagonists for the management of major depressive disorder: A systematic review of randomized clinical trials"],"prefix":"10.1016","volume":"372","author":[{"given":"Shakila","family":"Meshkat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela T.H.","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gia Han","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla M.","family":"Teopiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeho Greg","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2024.12.008_bb0005","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.biopha.2018.10.033","article-title":"Co-administration of the low dose of orexin and nitrergic antagonists induces an antidepressant-like effect in mice","volume":"109","author":"Alijanpour","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jad.2024.12.008_bb2005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.psyneuen.2013.10.010","article-title":"Anxiolytic function of the orexin 2\/hypocretin A receptor in the basolateral amygdala","volume":"40","author":"Arendt","year":"2014","journal-title":"Psychoneuroendocrinology"},{"issue":"19","key":"10.1016\/j.jad.2024.12.008_bb0015","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1021\/acschemneuro.1c00457","article-title":"Linking the triad of telomere length, inflammation, and gut dysbiosis in the manifestation of depression","volume":"12","author":"Bazaz","year":"2021","journal-title":"ACS Chem. Nerosci."},{"issue":"1","key":"10.1016\/j.jad.2024.12.008_bb0025","doi-asserted-by":"crossref","first-page":"7","DOI":"10.31887\/DCNS.2002.4.1\/bbondy","article-title":"Pathophysiology of depression and mechanisms of treatment","volume":"4","author":"Brigitta","year":"2002","journal-title":"Dialogues Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.jad.2024.12.008_bb0030","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/0269881118822258","article-title":"The selective orexin-2 receptor antagonist seltorexant improves sleep: an exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia","volume":"33","author":"Brooks","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2024.12.008_bb0035","article-title":"Orexin (hypocretin) neurons contain dynorphin","volume":"21(19):RC168","author":"Chou","year":"2001","journal-title":"J. Neurosci."},{"issue":"12","key":"10.1016\/j.jad.2024.12.008_bb0040","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/ijcp.12568","article-title":"Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic\u2013what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?","volume":"68","author":"Citrome","year":"2014","journal-title":"Int. J. Clin. Pract."},{"issue":"8","key":"10.1016\/j.jad.2024.12.008_bb0045","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/ijnp\/pyx033","article-title":"Phase II proof-of-concept trial of the orexin receptor antagonist filorexant (MK-6096) in patients with major depressive disorder","volume":"20","author":"Connor","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.jad.2024.12.008_bb0050","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41392-024-01738-y","article-title":"Major depressive disorder: hypothesis, mechanism, prevention and treatment","volume":"9","author":"Cui","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.jad.2024.12.008_bb0055","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1124\/jpet.109.152009","article-title":"Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat","volume":"330","author":"Dugovic","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jad.2024.12.008_bb0060","article-title":"Depression is the leading cause of disability around the world","volume":"317(15):1517","author":"Friedrich","year":"2017","journal-title":"Jama"},{"key":"10.1016\/j.jad.2024.12.008_bb0065","doi-asserted-by":"crossref","unstructured":"Ginsberg LD. Impact of drug tolerability on the selection of antidepressant treatment in patients with major depressive disorder. CNS spectrums. 2009;14(S12):8-14.","DOI":"10.1017\/S1092852900026353"},{"key":"10.1016\/j.jad.2024.12.008_bb0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/9781119536604.ch8","article-title":"Assessing risk of bias in a randomized trial","author":"Higgins","year":"2019","journal-title":"Cochrane handbook for systematic reviews of interventions"},{"issue":"8","key":"10.1016\/j.jad.2024.12.008_bb0075","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0028-3908(00)00010-1","article-title":"Neuropeptides\u2014an overview","volume":"39","author":"H\u00f6kfelt","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jad.2024.12.008_bb0085","doi-asserted-by":"crossref","unstructured":"Janto K, Prichard JR, Pusalavidyasagar S. An update on dual orexin receptor antagonists and their potential role in insomnia therapeutics. Journal of Clinical Sleep Medicine. 2018;14(8):1399-408.","DOI":"10.5664\/jcsm.7282"},{"issue":"1","key":"10.1016\/j.jad.2024.12.008_bb0090","first-page":"1","article-title":"The costs of depression","volume":"35","author":"Kessler","year":"2012","journal-title":"Psychiatric Clinics."},{"key":"10.1016\/j.jad.2024.12.008_bb0095","doi-asserted-by":"crossref","unstructured":"Kessler RC. The costs of depression. Psychiatric clinics. 2012b;35(1):1-4.","DOI":"10.1016\/j.psc.2011.11.005"},{"key":"10.1016\/j.jad.2024.12.008_bb0100","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.neubiorev.2020.07.040","article-title":"Dysregulation of the orexinergic system: a potential neuropeptide target in depression","volume":"118","author":"Khairuddin","year":"2020","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"2","key":"10.1016\/j.jad.2024.12.008_bb0105","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1210\/jcem.87.2.8246","article-title":"Reduction of plasma leptin levels and loss of its circadian rhythmicity in hypocretin (orexin)-deficient narcoleptic humans","volume":"87","author":"Kok","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"17","key":"10.1016\/j.jad.2024.12.008_bb0110","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1016\/j.bmcl.2013.06.057","article-title":"Selective orexin receptor antagonists","volume":"23","author":"Lebold","year":"2013","journal-title":"Bioorganic & medicinal chemistry letters"},{"issue":"6","key":"10.1016\/j.jad.2024.12.008_bb0115","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/da.22063","article-title":"Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions","volume":"30","author":"McIntyre","year":"2013","journal-title":"Depress. Anxiety"},{"issue":"1","key":"10.1016\/j.jad.2024.12.008_bb0120","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1176\/appi.ajp.20230922","article-title":"Psychotropic Drug\u2013Related Weight Gain and Its Treatment","volume":"181","author":"McIntyre","year":"2024","journal-title":"Am. J. Psychiatry"},{"issue":"11","key":"10.1016\/j.jad.2024.12.008_bb0125","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/17425255.2020.1817380","article-title":"Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders","volume":"16","author":"Muehlan","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"8","key":"10.1016\/j.jad.2024.12.008_bb0130","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1176\/appi.ajp.2020.20060845","article-title":"The state of our understanding of the pathophysiology and optimal treatment of depression: glass half full or half empty?","volume":"177","author":"Nemeroff","year":"2020","journal-title":"Am. J. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.jad.2024.12.008_bb0135","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.neuropharm.2011.04.022","article-title":"Activation of orexin neurons in dorsomedial\/perifornical hypothalamus and antidepressant reversal in a rodent model of depression","volume":"61","author":"Nollet","year":"2011","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.jad.2024.12.008_bb0140","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/npp.2012.70","article-title":"Neurogenesis-independent antidepressant-like effects on behavior and stress axis response of a dual orexin receptor antagonist in a rodent model of depression","volume":"37","author":"Nollet","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2024.12.008_bb2140","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40263-013-0064-z","article-title":"Role of orexin in the pathophysiology of depression: potential for pharmacological intervention","volume":"27","author":"Nollet","year":"2013","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.jad.2024.12.008_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2016.65","article-title":"Major depressive disorder","volume":"2","author":"Otte","year":"2016","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.jad.2024.12.008_bb0150","unstructured":"Page MJ, Moher D. Evaluations of the uptake and impact of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Statement and extensions: a scoping review. Systematic reviews. 2017;6(1):1-4.Recourt K, de Boer P, Zuiker R, Luthringer R, Kent J, van der Ark P, Van Hove I, van Gerven J, Jacobs G, van Nueten L, Drevets W. The selective orexin."},{"issue":"4","key":"10.1016\/j.jad.2024.12.008_bb0155","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13665","article-title":"The orexin story, sleep and sleep disturbances","volume":"31","author":"Pizza","year":"2022","journal-title":"J. Sleep Res."},{"issue":"1","key":"10.1016\/j.jad.2024.12.008_bb0160","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41398-019-0553-z","article-title":"The selective orexin-2 antagonist seltorexant (JNJ-42847922\/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder","volume":"9","author":"Recourt","year":"2019","journal-title":"Transl. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2024.12.008_bb0165","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1021\/acs.jmedchem.5b00832","article-title":"Orexin receptor antagonists: new therapeutic agents for the treatment of insomnia","volume":"59","author":"Roecker","year":"2016","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.jad.2024.12.008_bb0170","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0006-3223(02)01740-7","article-title":"Diurnal variation of cerebrospinal fluid hypocretin-1 (orexin-a) levels in control and depressed subjects","volume":"54","author":"Salomon","year":"2003","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2024.12.008_bb0175","doi-asserted-by":"crossref","first-page":"49178","DOI":"10.4088\/JCP.23br14923","article-title":"Dual orexin receptor antagonists and suicide risk: findings from the WHO spontaneous reporting database","volume":"84","author":"Salvo","year":"2023","journal-title":"J. Clin. Psychiatry"},{"issue":"12","key":"10.1016\/j.jad.2024.12.008_bb2175","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/ijnp\/pyab050","article-title":"Efficacy and safety of seltorexant as adjunctive therapy in major depressive disorder: a phase 2b, randomized, placebo-controlled, adaptive dose-finding study","volume":"24","author":"Savitz","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.jad.2024.12.008_bb0180","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.neulet.2010.07.038","article-title":"Cerebrospinal fluid hypocretin-1 (orexin a) levels in mania compared to unipolar depression and healthy controls","volume":"483","author":"Schmidt","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.jad.2024.12.008_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pnpbp.2018.12.008","article-title":"Evaluating the role of orexins in the pathophysiology and treatment of depression: a comprehensive review","volume":"92","author":"Shariq","year":"2019","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2024.12.008_bb0190","first-page":"52","article-title":"Assessment of suvorexant and eszopiclone as alternatives to benzodiazepines for treating insomnia in patients with major depressive disorder","volume":"45","author":"Shigetsura","year":"2022","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jad.2024.12.008_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2018.12.036","article-title":"Orexin\/hypocretin receptor modulation of anxiolytic and antidepressive responses during social stress and decision-making: potential for therapy","volume":"1731","author":"Summers","year":"2020","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/j.jad.2024.12.008_bb0200","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1046\/j.1532-5415.2003.51159.x","article-title":"Depression treatment in a sample of 1,801 depressed older adults in primary care","volume":"51","author":"Un\u00fctzer","year":"2003","journal-title":"J. Am. Geriatr. Soc."},{"issue":"2","key":"10.1016\/j.jad.2024.12.008_bb0205","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/bph.12261","article-title":"Discovery and development of orexin receptor antagonists as therapeutics for insomnia","volume":"171","author":"Winrow","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jad.2024.12.008_bb0210","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fnbeh.2017.00083","article-title":"Selective inhibition of orexin-2 receptors prevents stress-induced ACTH release in mice","volume":"11","author":"Yun","year":"2017","journal-title":"Front. Behav. Neurosci."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724019876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724019876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T13:56:03Z","timestamp":1740059763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032724019876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":42,"alternative-id":["S0165032724019876"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2024.12.008","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of orexin antagonists for the management of major depressive disorder: A systematic review of randomized clinical trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2024.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}